格隆汇8月28日丨海西新药(02637.HK)发布截至2026年6月30日止六个月，集团的营业收入约为人民币3.12亿元，同比增长3.85%；净利润为人民币8104.9万元，同比减少24.82%，主要由于子公司生产基地投入使用相比同期产生折旧人民币798.7万元，以及本年度研发费用增加所致。 截至本公告日，公司自主研发的核心创新药项目 HXP056之候选药物分子HX9428中美双中心临床同步推进，中国已完成I期临床，现阶段正在开展II期剂量扩展研究及第二项采用阳性对照的II期临床研究，美国FDA II期临床申请已获批，且获美国FDA授予快速通道资格；C019199骨肉瘤适应症III期注册临床研究获CDE批准且完成首例入组；HXP089项目用于治疗胶质母细胞瘤(Glioblastoma, GBM)的新药临床试验申请(IND)，已获国家药品监督管理局(NMPA)药品审评中心(CDE)批准开展相关临床研究；创新药管线进入密集收获期。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.